Maynard Um
-
-
-
-
-
-
-
RenovoRx starts multi-center registry study for cancer device
-
-
-
-
-
-
-
RenovoRx (RNXT) Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
-
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

